Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AZD5153 + Durvalumab + Selumetinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD5153||AZD-5153||BRD4 Inhibitor 10||AZD5153 is a selective BET inhibitor that binds to BRD4 bivalently, resulting in enhanced anti-tumor activity (PMID: 27573426, PMID: 31392631).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).|
|Selumetinib||Koselugo||AZD6244|ARRY-142886||MEK inhibitor (Pan) 23 MEK1 Inhibitor 25 MEK2 Inhibitor 23||Koselugo (selumetinib) inhibits mitogen-activated protein kinase kinases (MEK or MAPK/ERK kinases) 1 and 2, which may prevent the activation of MEK1/2-dependent effector proteins and transcription factors, reducing cellular proliferation in various cancers (PMID: 27467210). Koselugo (selumetinib) is FDA approved for use in pediatric patients of 2 years or older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05253131||Phase Ib/II||AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib||Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas||Not yet recruiting||USA||0|